Cannabis for MS in Question

CannabisWhile cannabis was previously recommended by experts for multiple sclerosis, the benefits from the drug are now being questioned by a team of scientists, a new report has found.

A team of researchers from the Peninsula College of Medicine and Dentistry at Plymouth University is now of the opinion that the drug is no better than a standard drug like placebo.

The team had carried out a trial in 2006 in which around 500 people with progressive MS from 27 centers across the UK were recruited. All the participants were told to take either placebo or the cannabis drug for a period of three years.

Following the same, the people were involved in study dubbed Cupid i. e. cannabinoid use in progressive inflammatory brain disease, were examined on two scales. A disability scale managed by neurologists and the other was on the basis of participants’ own reporting.

The study funded by the Medical Research Council has led the team to conclude that the beliefs that the drug with key active ingredient tetrahydrocannabinol (THC) provides long-term benefits are wrong. The benefits of placebo were just the same.

However, David Nutt, professor of neuropsychopharmacology at Imperial College London, says, “Cannabis is not licensed for limiting disease progression; it is licensed for dealing with spasticity and pain”.